Abstract. In this study, we performed a proteomic analysis of sera from stage I gastric cancer patients using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and established a diagnostic model for the early diagnosis of stage I gastric cancer. Serum samples from 169 gastric cancer patients and 83 age- and gender-matched healthy individuals were analyzed by SELDI-TOF-MS ProteinChip array technology. The SELDI-TOF-MS spectral data were analyzed using the Biomarker Wizard™ and Biomarker Patterns™ software to find differential proteins and develop a classification tree for gastric cancer. A total of 34 mass peaks were identified. Six peaks at a mass-to-charge ratio (m/z) of 2873, 3163, 4526, 5762, 6121 and 7778 were used to construct the diagnostic model. The model effectively distinguished gastric cancer samples from control samples, achieving a sensitivity and specificity of 93.49 and 91.57%, respectively. In addition, we identified 3 of the 6 protein peaks at 2873, 6121 and 7778 m/z, which distinguished between stage I and stage II/III/IV gastric cancer. The model had an accuracy of 88.89% for the identification of stage I gastric cancer. In conclusion, the diagnostic model for the detection of serum proteins by SELDI-TOF-MS ProteinChip array technology correctly distinguishes gastric cancer from healthy samples, and has the ability to screen and distinguish between early gastric cancer from advanced gastric cancer.

Introduction

Gastric cancer is the fourth most common malignancy and second leading cause of cancer-related mortality worldwide (1). Almost two-thirds of gastric cancer cases and deaths occur in less developed regions, including China (2). Although with the development and refinement of radiographic upper gastrointestinal examination and endoscopy, neoadjuvant treatment and surgical treatment have undergone significant changes in the past decades, the prognosis for gastric cancer patients remains poor. Its prognosis is determined by clinical stage. According to a previous study, the estimated adjusted survival 5 years after surgery is 82.9% for stage I, 62.8% for stage II, 17.8% for stage III and 3.3% for stage IV patients (3). Overall 5-year survivals of approximately 20% or less are frequently reported.

The early diagnosis and early treatment of gastric cancer patients is the key to improving prognosis. When gastric cancers confined to the mucosa or submucosa are identified at an early stage, the 5-year survival is 90% or more (3-5). Thus, the identification of early-stage disease may be the most promising method to reduce gastric cancer mortality. Currently, endoscopic biopsy and histopathological evaluation of tumor resection margins are considered as a gold standard in the diagnosis of gastric cancer. However, this technique has evident disadvantages, in that it is invasive, time-consuming and expensive. More importantly, many patients are diagnosed with gastric cancer when metastasis has already occurred, thus limiting treatment efficacy. Additionally, the considerable expense of endoscopic biopsy or histopathological evaluation of tumor resection margins weakens the cost-effectiveness when screening programs for large populations are developed. Therefore, it is necessary to develop molecular biological techniques which are less invasive and more sensitive to improve the early diagnostics of gastric cancer. The identification of tumor biomarkers with high specificity and sensitivity would be desirable for the screening and diagnosis of early gastric cancer.

Biomarkers are defined as biological variables that correlate with biological outcome, and cancer biomarker discovery strategies that target expressed proteins are becoming increasingly popular (7). A great deal of effort has been spent in the search of tumor biomarkers, in order to improve the understanding of the behavior of gastric cancer and to identify...
family history of gastric cancer, and were followed-up for up to 10 years. Few studies have simultaneously evaluated more than one candidate biomarker to enhance the diagnostic sensitivity and specificity. At the same time, these studies have led to the belief that no single biomarker is likely to prove sufficiently predictive (11,12). Therefore, a logical development to improve the early diagnosis of cancer is to simultaneously screen for multiple biomarkers to increase the probability of detection (13-15).

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) ProteinChip is an innovative proteomic technology that enables the high-throughput analysis of a variety of serum samples from patients with gastric cancer and healthy controls, for the discovery of multiple specific protein biomarkers that could be used for the early diagnosis of gastric cancer. It has the advantages of being simple to operate, it is fast, and provides high throughput screening, high sensitivity and specificity. Over the years, SELDI-TOF-MS has been successfully applied in many types of tumors. A number of biomarkers in this process have been identified and further characterized, associated with cancers such as breast (16-18), liver (19-21), lung (22,23), prostate (24) and ovarian cancers (25). These studies suggest that SELDI-TOF-MS ProteinChip technology can distinguish cancer patients from normal subjects with relatively high sensitivity and specificity. Thus, SELDI proteomic analysis is a valuable method to detect biomarkers or profile biomarkers within different sample groups; for example healthy individuals and cancer patients (26). However, at present, there are no satisfactory diagnostic biomarkers for early gastric cancer. The purpose of our study was to perform a proteomic analysis of sera from gastric cancer patients using SELDI-TOF-MS, and establish a useful diagnostic model for identifying gastric cancer or early gastric cancer.

Materials and methods

Study population. Consecutive patients with primary gastric cancer were prospectively considered from September 1, 2009 to September 1, 2010 at the Affiliated Hospital of Medical College, Qingdao University. All of the patients were diagnosed by histological examination. Patients who had received prior treatment before admission were excluded. To be eligible for enrollment, the subjects had to belong to the Chinese Han population. The protocol was approved by the Ethics Committee of Qingdao University, and informed consent was obtained from each patient or a close relative. Tumor TNM staging was recorded according to the classification of the American Joint Committee on Cancer (7th ed., 2010). We also excluded all of the volunteers and gastric cancer patients with infectious diseases, such as acute inflammation, viral HIV, HBV and HCV infections, as well as other serious diseases. The controls were recruited from hospital attendees in 2 centers with no family history of gastric cancer, and were followed-up for up to a maximum of 5 years, in which none developed gastric cancer. They were matched with patients for age and gender, without any malignant diseases and infectious disorders.

 Serum samples. Immediately after admission and prior to any surgical or medical procedure, 5 ml of peripheral blood samples were collected from patients on an empty stomach early in the morning, and placed in glass tubes without additive (BD Vacutainer™; BD Vacutainer Systems, Franklin Lakes, NJ, USA). The blood was centrifuged at 2,000 rpm for 10 min within 4 h after collection, and then stored at -80°C until detection.

ProteinChip analysis. An aliquot of the stored sera was used for the SELDI-TOF-MS analysis. The SELDI-TOF-MS technology (Ciphergen Biosystems, Fremont, CA, USA) consists of 3 major components: the ProteinChip array, the reader and the software. The ProteinChip array is a 10-mm wide 680-mm long chip with 8 2-mm spots comprised of a specific chromatographic surface. Each surface is designed to select proteins from crude extracts according to general or specific protein properties. Each spot contains either a chemically- (anionic, cationic, hydrophobic or metal) or biochemically-treated surface. In our experiments, a cationic exchanger (WCX2) was used. In brief, 10 µl of each serum sample and 90 µl of a solution containing 0.5% CHAPS (Sigma Inc., St. Louis, MO, USA) in phosphate-buffered saline (pH 7.4) were added to each well of a 96-well plate. The mixture was vortex-mixed at 4°C for 15 min, followed by the addition of 100 µl of Cibacron Blue 3GA (Sigma; prepared and balanced in 0.5% CHAPS 3 times). The plates were placed on a platform shaker at 4°C for 60 min. After centrifugation, the supernatant (40 µl) was transferred onto the WCX2 chips, so that each chip (8-spot format) held 4 tumorous and 4 healthy samples to rule out systematic error. All samples, including the training set, test set and normal serum quality control (QC) sample, were positioned randomly on the chips. The chips were placed in a bioprocessor (Ciphergen Biosystems Inc.), which holds 12 chips and allows a larger volume of serum to be applied to each chip array. The samples were allowed to react with the surface of the WCX2 chip for 60 min at room temperature. The chips were then washed 3 times by gentle agitation on a platform shaker at a speed of 700 rpm for 5 min with 200 µl of 20 mmol/l HEPES (pH 7.4), air dried and crystallized by the addition of α-cyano-4-hydroxycinnamic acid (CHCA; Ciphergen Biosystems Inc.). The chips were read on a protein biological system II (PBS-II) mass spectrometer reader (Ciphergen Biosystems Inc.). All spectra were compiled, and qualified mass peaks (signal-to-noise ratio >5) with mass-to-charge ratios (m/z) between 2,000 and 30,000 were autodetected. Peak clusters were completed using second pass peak selection (signal-to-noise ratio >2, within a 0.3% mass window), and estimated peaks were added. The relative peak intensities, normalized to a total ion current of m/z between 2,000 and 30,000, were expressed as arbitrary units. All these were performed using ProteinChip Software 3.0.2 (Ciphergen).

Statistical analysis. Peak intensities were normalized by total ion currency and analyzed by Biomarker Wizard software (Ciphergen Biosystems Inc.) to identify the peaks showing significantly different intensities between normal and cancer.
groups. The Mann-Whitney U test was used for statistical analysis of differences between the cancer group and the control group. Classification analysis and construction of decision trees were performed with the Biomarker Patterns software 5.0 (Ciphergen Biosystems Inc.). A discriminatory pattern that distinguished normal from gastric cancer samples was developed from a training set of mass spectra; this diagnostic pattern was then applied to a blinded set of samples from cancer patients and healthy subjects.

Results

A total of 252 serum samples, including 169 pathologically confirmed gastric cancer patients (group 1 included 27 stage I, 45 stage II, 56 stage III and 37 stage IV patients) and 83 healthy subjects (group 2) were collected (Table I). The reproducibility of the ProteinChip SELDI assays using the pooled sera from 83 control samples was determined. Four chip chemistries [hydrophobic surface, immobilized metal affinity capture, weak cation exchange (WCX-2) and strong anion exchange] were evaluated to investigate which provided the best serum profile. Our determinations revealed that the WCX-2 chip provided the most discriminating pattern for constructing a decision tree (Table II). The peaks were analyzed in the mass range of 2,000 to 30,000 m/z and a total of 34 mass peaks were identified.

Biomarker characteristics of serum from gastric cancer patients and normal volunteers. There were statistical differences between 6 protein peaks located at 2873, 4526, 5762, 6121 and 7778 m/z (P<0.05); the intensity of protein peaks at 2873 m/z in the sera from patients with gastric cancer was clearly higher than that of the healthy controls (P<0.05). Bi-peak and tri-peaks (5762 and 3163 m/z) were also observed in the sera from patients with gastric cancer. Furthermore, the protein peaks at 7778, 4526 and 6121 m/z were down-regulated compared to normal healthy volunteers (Table III). Using the above profiles, 158 of the 169 patients diagnosed pathologically with gastric cancer were correctly identified by SELDI. Seventy-six of the 83 healthy volunteers were correctly identified as normal. The sensitivity of gastric cancer identification was 93.49% (158/169) for patients, whereas the specificity of control verification was 91.57% (76/83).

Biomarker characteristics of serum from stage I and stage II/III/IV gastric cancer patients. In the mass spectral patterns identified above, we observed that 3 protein peaks (2873, 5762 and 7778 m/z) were differentially expressed in early gastric cancer (stage I) compared to stage II, III and IV cases. Using these criteria, stage I gastric cancer was correctly identified in 24 out of 27 samples. Therefore, SELDI-TOF-MS can distinguish between stage I and stage II/III/IV gastric cancer. The biomarkers had an accuracy of 88.89% for the identification of stage I gastric cancer.

Discussion

Early diagnosis improves the long-term survival chances of patients with stomach cancers, and currently no satisfactory biomarkers for the diagnosis of early gastric cancer exist. It is very important to develop a convenient and non-invasive
diagnostic method for routine screening and thereby increase the early diagnosis of cancers, which may lead to more patients being cured and reduced mortality. However, there are several obstacles in identifying serum biomarkers for cancer. Many potentially valuable biomarkers are expressed at very low levels and are difficult to detect. In addition, protein concentrations are unstable and may change with stress, disease or treatment. Proteins can be modified by cleavage or by the addition of new functional groups.

In our study, we analyzed protein expression patterns in sera obtained from gastric cancer patients and normal controls using the SELDI ProteinChip array, and constructed 2 decision trees for differentiating gastric cancer patients from normal individuals. Six peaks of 2873, 4526, 3163, 5762, 6121 and 7778 m/z were used to discriminate the 2 groups; of note, 3 peaks, 2873, 6121 and 7778 m/z, were differentially expressed in stage I gastric cancer compared to stage II, III and IV cases. The 2 decision trees constructed using those peaks showed high sensitivity and specificity in discriminating stage I gastric cancer, stage II/III/IV gastric cancer patients and controls.

Notably, several studies have addressed serum-based molecular markers, but each study showed different mass peaks and divergent results. Lu et al analyzed 65 serum samples from gastric cancer patients (27). Five protein peaks at 2046, 3179, 1817, 1725 and 1929 m/z were components of the biomarker pattern for the diagnosis of gastric cancer, and 1 protein peak (4665 m/z) distinguished between stage I/II and stage III/IV with a specificity and sensitivity of 91.6% (11/12) and 95.4% (21/22), respectively. The detection range of the mass peak (1,500-20,000 Da) was different from ours (2,000-30,000 Da). This may have caused the disparity between the results of our 2 studies.

Another decision tree analysis of serum proteomic patterns was performed by Anderson et al (28). They showed that 8 of 9 stage I gastric cancers (88.9% sensitivity for stage I) were correctly classified. It is very important study for the detection of stage I gastric cancers by SELDI-TOF-MS, but they studied few cases. Ebert et al (29) constructed a decision tree by analysis serum proteomic patterns. Their system was capable of differentiating the gastric cancer samples from the others with a specificity of 88.0% and a sensitivity of 85.3%. Unlike the previous study, Su et al used SAX2 (strong anionic exchanger) chips. Liang et al showed that the comparison of protein expression profiles from serum appears to provide an effective approach to identify unique biomarkers for gastric cancer and gastritis, but they did not construct model trees using mass peaks (30).

Our findings are in general agreement with those reported by previous authors, thus providing additional confirmation that a proteomic approach accurately identifies gastric cancer patients from healthy controls. We also show a potential advantage of SELDI-TOF-MS, which is the ability to detect stage I gastric cancer. This may have significant implications for its utility in screening for early gastric cancer. Although the limitations of SELDI-TOF-MS study design and its analysis have been discussed in some detail in the literature (31), the potential implications of such a proteomic spectrum analysis for the identification of novel tumor biomarkers are huge.

In conclusion, we set up 2 serum proteomic patterns by SELDI-TOF-MS that have potential for clinical use. This analysis distinguishes gastric cancer patients from healthy controls, and has the ability to screen and distinguish between early gastric cancer from advanced gastric cancer. Using the diagnostic patterns to diagnose early gastric cancer can obtain a higher positive rate, higher sensitivity and specificity. Therefore, it seems desirable to know the identity of the biomarkers in the pattern in order to understand their significance in gastric cancer pathogenesis, staging and prognosis. We hope in the future to identify these protein peaks and combine them with other markers, such as CEA or CA199 or CA125, to assess therapeutic response and increase early detection of early gastric cancer.

Acknowledgements

This study was supported by the Shandong Scientific and Technological Project (2008GG30002034).

References